StockData
Ionis Pharmaceuticals Inc logo

Ionis Pharmaceuticals Inc (IONS) stock

IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/301% below fair value
$28.01−1.05 (-3.61%)

Close on Nov 16, 2026Market cap $4.65BP/E –Yield –

Ionis Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $915.62M, up 1.6% from the year before. Over ten years it grew 14.4% a year on average. The highest annual figure on record is $915.62M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$915.62M+1.6%
FY2024Dec 31, 2024$901.53M+0.2%
FY2023Dec 31, 2023$899.63M+41.0%
FY2021Dec 31, 2021$638.20M+20.2%
FY2020Dec 31, 2020$531.00M+15.1%
FY2019Dec 31, 2019$461.50M+12.0%
FY2018Dec 31, 2018$411.90M+10.6%
FY2017Dec 31, 2017$372.50M+9.4%
FY2016Dec 31, 2016$340.40M+6.5%
FY2015Dec 31, 2015$319.50M+33.7%
FY2014Dec 31, 2014$238.90M+37.5%
FY2013Dec 31, 2013$173.70M+12.4%
FY2012Dec 31, 2012$154.60M+1.0%
FY2011Dec 31, 2011$153.10M+5.5%
FY2010Dec 31, 2010$145.16M+7.8%
FY2009Dec 31, 2009$134.62M+26.5%
FY2008Dec 31, 2008$106.44M–

More Ionis Pharmaceuticals figures

See a number that looks wrong?